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use#LAACancer is a disease of uncontrolled cell growth in which 
cells  acquire  genetic  alterations  that  allow  them  to 
proliferate outside the context of normal tissue develop­
ment.  In  the  evolution  of  this  transformation,  cells 
acquire mutations that confer selective advantages for the 
growth of the tumor. Genetic alterations in many of the 
known oncogenes are selected to adapt cellular metabo­
lism to meet the requirements of rapid cell proliferation 
as  well  as  autonomous  growth  and  survival  in  an 
environment absent of contact with extracellular matrix 
(Figure 1). Accumulating evidence indicates that almost 
every  known  oncogene  regulates  downstream  targets 
that are directly connected to metabolic regulation [1]. A 
detailed biochemical and systems­level understanding of 
precisely how oncogenes rewire metabolism is essential 
to understand tumor biology, but concomitantly requires 
an assessment of the metabolic adaptations required to 
support the proliferation of cancer cells. Understanding 
the consequences of this differential metabolism requires 
a  thorough  analysis  of  glucose  metabolism  and  its 
relation to energy production in cancer cells.
In  a  majority  of  tumor  types,  an  enhanced  rate  of 
glucose  uptake  is  observed  and  serves  as  a  reasonable 
starting point for understanding differential metabolism 
in tumors. Otto Warburg’s initial observation that tumors 
often  metabolize  relatively  large  quantities  of  glucose 
predominantly through a fermentative­like metabolism, 
resulting  in  lactate  production  in  aerobic  conditions 
(termed aerobic glycolysis), provided the phenomeno  lo­
gi  cal  foundation  for  studying  altered  metabolism  in 
cancer [2]. Rapid progress is being made towards a mole­
cular  understanding  of  why  lactate  production  from 
glucose gives cancer cells a growth advantage. Paradoxically, 
cells that achieve high rates of aerobic glycolysis often 
show  relatively  small  changes  in  the  rate  of  oxygen 
consump  tion in response to changes in glucose uptake; 
that is, oxidative catabolic flux through the Krebs cycle 
leading  to  mitochondrial  ATP  generation  is  somewhat 
independent of glucose metabolism [3].
Alternative metabolic fluxes support the Krebs 
cycle and mitochondrial ATP production
Catabolic  pathways  involving  the  oxidation  of  material 
other than glucose in the Krebs cycle are also involved in 
cancer cell metabolism. For example, glutamine flux into 
the Krebs cycle has been directly observed in cancer cell 
lines and appears to be in part regulated by expression of 
MYC and TP53 (p53) ­ two of the most common cancer­
associated genes [4­6]. Additional amino acids such as 
arginine and glycine, and metabolic intermediates such 
as fatty acids, can also be metabolized by mitochondrial 
pathways  in  certain  contexts.  These  metabolites  have 
trans  porters to deliver them into cells and are present in 
sufficiently high plasma concentrations to support their 
use  in  catabolic  metabolism  in  mitochondria  [7].  In 
addition, many of the anabolic products that stem from 
intermediates in glycolysis can ultimately flow into the 
Krebs  cycle,  resulting  in  a  bypass  of  the  generation  of 
pyruvate  ­  the  end  product  of  glycolysis.  This  type  of 
glucose  metabolism  avoids  metabolic  activity  involving 
pyruvate kinase and pyruvate dehydrogenase, which are 
typically inhibited in cancer cells [8]. These alternative 
pathways  present  many  opportunities  for  additional 
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Cancer cells have different metabolic requirements 
from their normal counterparts. Understanding the 
consequences of this differential metabolism requires 
a detailed understanding of glucose metabolism 
and its relation to energy production in cancer cells. 
A recent study in BMC Systems Biology by Vasquez et 
al. developed a mathematical model to assess some 
features of this altered metabolism. Here, we take a 
broader look at the regulation of energy metabolism 
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to  anabolic  versus  catabolic  metabolism,  and  more 
research is required to understand the origins and tumor 
specificities of Krebs cycle flux.
ATP requirements in tumor cells
Aerobic  glycolysis  is  considered  a  relatively  inefficient 
way of producing ATP, as the alternative catabolic fate of 
glucose via oxidation in the Krebs cycle and donation of 
electrons into the electron­transport chain can generate 
15 to 20 times as much ATP per unit of glucose. A recent 
study by Vazquez et al. [9] used a reduced flux­balance 
model  to  suggest  that  synthesizing  ATP  from  glucose 
through aerobic glycolysis is the optimal ATP­generating 
strategy when a cell is limited by its capacity to maintain 
enough  mitochondrial  mass  to  support  sufficient  flux 
through the electron­transport chain. Whether fermen­
ta  tion is an optimal ATP­generating strategy is unclear; 
however, there are several lines of evidence that suggest 
that  tumor  cell  proliferation  is  not  limited  by  ATP 
availability.
For mammalian cells, calculations suggest that most of 
the  ATP  generated  is  consumed  in  basal  cellular 
processes  such  as  the  maintenance  of  concentration 
gradients through ion pumps and active transport using 
molecular motors. A simple calculation shows that bio­
syntheses are not a major source of ATP consumption in 
tumor cells [10]. As shown in Figure 2, ATP requirements 
for  maintenance  and  proliferation  can  be  plotted  as  a 
function of cell doubling time. For cells that divide on the 
order of minutes, most of the ATP is used for cell growth. 
However, for cells that divide on the order of days, such 
as those in tumor tissue, almost all the ATP is used for 
cell maintenance. One possible source of confusion about 
ATP generation in tumor cells is that the apparent lack of 
demand  for  ATP  in  cell  proliferation  is  in  contrast  to 
bacteria and other unicellular organisms. These micro­
organisms undergo rapid cell division on a time scale of 
minutes and it is estimated that most of their ATP is used 
for biosynthesis. In all, the calculations suggest that the 
Warburg  effect  may  not  be  related  to  a  cell’s  optimal 
ability to generate ATP. Furthermore, as we discuss next, 
ATP  hydrolysis  can  be  a  limiting  factor  required  to 
support high rates of glycolysis.
Stoichiometric consequences of high rates of 
glycolysis
The  stoichiometry  of  glycolysis  imposes  chemical  con­
straints when high fluxes of glucose occur. Consider the 
overall  chemical  equation  for  conversion  of  glucose  to 
pyruvate via glycolysis:
C6H12O6 + 2Pi + 2ADP + 2NAD+ →2C3H3O3 + 2H2O + 
2ATP + 2NADH
From  the  equation,  it  is  clear  that  glycolysis  is  not 
possible  without  sufficient  regeneration  of  ADP  and 
NAD+.  The  reduction  of  pyruvate  to  lactate  by  lactate 
dehydrogenase is the most ubiquitous mechanism known 
for  converting  NADH  back  to  NAD+,  and  this  activity 
balances the very high rate of glycolysis observed in most 
cancer  cells.  Efraim  Racker  noted  the  problem  of 
stoichio  metric ADP availability and postulated that large 
Figure 1. Cell-autonomous control of growth and metabolism 
are acquired upon cell transformation by mutation. Cells in a 
normal tissue (left-hand diagram) are constrained in their growth by 
their environment (depicted as green lines). During the development 
of a tumor (right-hand diagram), cells acquire mutations that allow 
growth outside the context of normal tissue development. As a 
result, metabolic pathways are reorganized and metabolism is altered 
to allow for cell-autonomous growth.
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Figure 2. ATP requirements in cell maintenance and division. 
Using a model based on differential equations for growth rates [10], 
the fraction of ATP, fATP, consumed for biosynthetic (red dashed line) 
versus maintenance (black dashed line) purposes in cells is plotted 
as a function of doubling time in days. Typical doubling times for 
unicellular organisms such as Escherichia coli and Saccharomyces 
cerevisiae are shown, as well as for typical cancer cell lines (HeLa) and 
solid tumors.
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hydrolysis reactions were required to balance the cellular 
glucose uptake rates found in tumors. Futile cycles, more 
conveniently directly coupled to glycolysis, that hydrolyze 
ATP  were  believed  to  be  required  to  balance  high 
glycolytic flux [11]. One now established example of a 
futile cycle in glycolysis involves a shunting step in which 
fructose  6­phosphate  (F6P)  is  phosphorylated  to  form 
fructose 2,6­bisphosphate, which is then dephosphory­
lated  back  to  F6P,  resulting  in  net  ATP  hydrolysis. 
Attention has recently been paid to the cancer specificity 
of  these  reactions  and  some  studies  suggest  that  the 
enzyme activity responsible may be differentially regu­
lated in some cancers [12]. Other ATP­consuming futile 
cycles in central carbon metabolism may yet be discovered.
Growth advantages of aerobic glycolysis
Although  aerobic  glycolysis  may,  by  virtue  of  stoichio­
metry, be necessary to support high rates of glycolysis, 
the  advantages  of  this  process  for  tumor  cells  are 
complicated to understand. Cell­autonomous effects of 
lactate  secretion  are  likely  to  confer  advantages  on 
tumors. Lactate may enhance the invasiveness of tumor 
cells by disrupting normal tissue architecture as well as 
promoting  an  environment  with  reduced  pH  to  evade 
tumor­attacking immune cells.
A complementary teleology suggests that maintaining 
high rates of glycolysis is required to reconfigure meta­
bolic pathway fluxes to achieve more efficient anabolic 
metabolism and cell­autonomous growth. One specula­
tion  is  that  a  movement  of  pathway  fluxes  towards 
anabolic metabolism can arise from the effects of differ­
en  tial ATP hydrolysis and redox balance that originate 
from  the  demands  of  the  stoichiometry  shown  in  the 
equation  above.  These  differential  pathway  fluxes  are 
likely  to  be  dependent  on  tumor  type  since  different 
oncogenes are used to regulate different anabolic fluxes.
Cancer  cells  are  limited  in  their  growth  by  the 
availability of carbon skeletons needed to produce new 
proteins,  nucleotides  and  lipids  [13].  Furthermore,  the 
reducing equivalents in the form of NADPH required for 
reductive  biosynthesis  derive  from  pathways  that  are 
orthogonal to ATP­generating pathways. Multiple solu­
tions  to  the  problem  of  obtaining  sufficient  carbon 
material  and  reducing  equivalents  are  obtainable,  and 
probably depend on the genetic context of the tumor and 
its microenvironment. A comprehensive understanding 
of how NADPH is generated and used in cells, and the 
predominant  anabolic  carbon  fluxes  stemming  from 
glucose uptake, will help to parse the molecular conse­
quences of aerobic glycolysis.
Because  of  the  complexity  of  cancer  metabolism,  a 
better  understanding  will  ultimately  require  the  use  of 
mathematical models. This improved understanding will 
then  allow  intervention  in  the  metabolic  pathways 
responsible for tumor cell metabolism. Exploiting these 
tumor­specific  properties  presents  opportunities  for 
therapeutic  intervention  in  tumor  development.  The 
pharmacological targeting of enzymes that regulate this 
restructured  metabolism  has  recently  shown  some 
promise in preclinical studies [14].
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